Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise

Nature Reviews Clinical Oncology, Published online: 30 September 2019; doi:10.1038/s41571-019-0267-4The use of epigenetic drugs (epi-drugs) as single agents according to a ‘one size fits all’ approach has generally resulted in disappointing therapeutic activity. In this Review, the mechanisms by which epi-drugs can modulate the sensitivity of cancer cells to other diverse forms of anticancer therapy are described, and completed and ongoing clinical trials relating to combination therapies incorporating epi-drugs are discussed. In addition, clinical trial designs and drug development strategies aimed at optimizing the development of such combinations are outlined.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research